Despite the increasing use and success of interventional coronary reperfusion strategies,
morbidity and mortality from acute myocardial infarction are still substantial. Myocardial …

Ischemic heart disease still represents a large burden on individuals and health care
resources worldwide. By conventions, it is equated with atherosclerotic plaque due to flow …

The present study aimed to investigate whether dexmedetomidine (Dex) exerts
cardioprotection effect through inhibiting ferroptosis. Myocardial ischemia/reperfusion injury …

Background Prompt myocardial revascularization with percutaneous coronary intervention
(PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation …

Mitophagy preserves microvascular structure and function during myocardial
ischemia/reperfusion (I/R) injury. Empagliflozin, an anti-diabetes drug, may also protect …

Myocardial infarction (MI) is the irreversible death of cardiomyocyte secondary to prolonged
lack of oxygen or fresh blood supply. Historically considered as merely cardiomyocyte …

Acute myocardial infarction (AMI) and the heart failure (HF) that often follows are among the
leading causes of death and disability worldwide. As such, new treatments are needed to …

Background Remote ischaemic conditioning with transient ischaemia and reperfusion
applied to the arm has been shown to reduce myocardial infarct size in patients with ST …

The exosome of MSCs derived from human umbilical cord blood (HUCB-MSC) has been
reported to have cardioprotective effects on mouse models of acute myocardial infarction …

Background Empagliflozin has been reported to protect endothelial cell function, regardless
of diabetes status. However, the role of empagliflozin in microvascular protection during …